Effects of Low-Dose and Very Low-Dose Ketamine among Patients with Major Depression: a Systematic Review and Meta-Analysis
Open accessThe DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Several recent trials indicate low-dose ketamine produces rapid antidepressant effects. However, uncertainty remains in several areas: dose response, consistency across patient groups, effects on suicidality, and possible biases arising from crossover trials. METHODS: A systematic search was conducted for relevant randomized trials in Medline, Embase, and PsycINFO databases up to August 2014. The primary endpoints were change in depression scale scores at days 1, 3 and 7, remission, response, suicidality, safety, and tolerability. Data were independently abstracted by 2 reviewers. Where possible, unpublished data were obtained on treatment effects in the first period of crossover trials. RESULTS: Nine trials were identified, including 201 patients (52% female, mean age 46 years). Six trials assessed low-dose ketamine (0.5 mg/kg i.v.) and 3 tested very low-dose ketamine (one trial assessed 50 mg intra-nasal spray, another assessed 0.1-0.4 mg/kg i.v., and another assessed 0.1-0.5 mg/kg i.v., intramuscular, or s.c.). At day 3, the reduction in depression severity score was less marked in the very low-dose trials (P homogeneity <.05) and among bipolar patients. In analyses excluding the second period of crossover trials, response rates at day 7 were increased with ketamine (relative risk 3.4, 95% CI 1.6-7.1, P=.001), as were remission rates (relative risk 2.6, CI 1.2-5.7, P=.02). The absolute benefits were large, with day 7 remission rates of 24% vs 6% (P=.02). Seven trials provided unpublished data on suicidality item scores, which were reduced on days 1 and 3 (both P<.01) but not day 7. CONCLUSION: Low-dose ketamine appears more effective than very low dose. There is substantial heterogeneity in clinical response, with remission among one-fifth of patients at 1 week but most others having benefits that are less durable. Larger, longer term parallel group trials are needed to determine if efficacy can be extended and to further assess safety.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ketamine, a glutamatergic agent used routinely for induction and maintenance of anesthesia, exhibits well-replicated, rapid, potent antidepressant effects in randomized controlled trials (i.e., metaanalytic Cohen's d=1.4, a large effect) 12 , even in difficult-to-treat conditions such as treatment-resistant depression 32 and bipolar depression 33 .”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Approach: Intravenous ketamine Evidence: Strong support 12”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As an example, we discuss the potential for ketamine-which exhibits both rapid plasticity-enhancing effects in animal models 4,10 and rapid clinical effects in human patients 11,12 -to provide a test of the predictions of this integrative model, including simultaneous and correlated reversals of multiple plasticity-related deficits across levels of analysis.”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [12]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Larkin, G. L., & Beautrais, A. L. (2011) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000629 · Cited by 258 · cited 2×
“…or even enhanced by repeated dosing, such as the 2 to 3 times weekly schedule that has been assessed in some case series with promising findings (Price et al., 2009; aan het Rot et al., 2010; DiazGranados et al., 2010b; Larkin and Beautrais, 2011; Rasmussen et al., 2013; Shiroma et al., 2014).”
BackgroundRetractedHamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 4×
“The primary endpoint was change in depression severity scores from baseline on depression scales such as the Hamilton Depression Rating Scale (HAM-D; Hamilton, 1960) and/or the Montgomery Åsberg Depression Rating Scale [MADRS]) at the following times: day 1 (24 hours after first dose), day 3, and day 7.”
MethodInfluentialCochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048 · cited 3×
“The I2 statistic was used to assess heterogeneity of trial results, and subgroup heterogeneity was tested using a chi-squared statistic (Higgins and Green, 2009).”
MethodA new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090 · cited 3×
“Diverse measures were used to test possible psychotomimetic, dissociative, or mood elevation symptoms, including Visual Analogue Scale score for intoxication “high” (Aitken, 1969), Brief Psychiatric Rating Scale (Overall and Gorham, 1962), Young Mania Rating Scale (Young et al., 1978), and Clinician Administered Disso…”
MethodA Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744 · cited 3×
“Diverse measures were used to test possible psychotomimetic, dissociative, or mood elevation symptoms, including Visual Analogue Scale score for intoxication “high” (Aitken, 1969), Brief Psychiatric Rating Scale (Overall and Gorham, 1962), Young Mania Rating Scale (Young et al., 1978), and Clinician Administered Disso…”
MethodMolecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 8×
“The results showed that Visual Analogue Scale score for intoxication “high” scores returned to baseline within 110 minutes of the infusion (Berman et al., 2000).”
BackgroundMethodResultInfluentialA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 1×
“Several additional strands of evidence indicate that the benefit observed in these trials is a result of depression treatment, rather than nonspecific mood elevation or a ‘high’ following ketamine administration: there is improvement in core depressive symptoms such as sadness, suicidality, and helplessness; the time…”
Background
Research works printed but not linked: 2
- Aitken, 1969, Measurement of feelings using visual analogue scales, Proc R Soc Med, 62, 989
- RevMan (2014) The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Cited by
Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model
Price, R. B., & Duman, R. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0615-x · Cited by 739
Schwenk, E. S., Viscusi, E. R., Buvanendran, A., Hurley, R. W., Wasan, A. D., Narouze, S., Bhatia, A., Davis, F. N., Hooten, W. M., & Cohen, S. P. (2018) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000806 · Cited by 584
A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders
Sanacora, G., Frye, M. A., McDonald, W., Mathew, S. J., Turner, M. S., Schatzberg, A. F., Summergrad, P., Nemeroff, C. B., & for the American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0080 · Cited by 576
“and oxygen saturation or end-tidal CO2; (3) criteria for acceptable baseline vital signs before initiation of medication delivery (eBox 2 in the Supplement); and (4) incorporation of a “time-out” procedure in which the name of the patient and correct dosing parameters are confirmed.”
BackgroundSide-effects associated with ketamine use in depression: a systematic review
Short, B., Fong, J., Galvez, V., Shelker, W., & Loo, C. K. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30272-9 · Cited by 558
Self-citationManagement of Treatment-Resistant Depression: Challenges and Strategies
Voineskos, D., Daskalakis, Z. J., & Blumberger, D. M. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s198774 · Cited by 446
“1,58,89,99 On average, the effects of ketamine appear to come on rapidly and last approximately 5 – 7 days 145 with a preferential treatment effect in individuals with comorbid anxiety or an “ anxious depression ” .”
Bahji, A., Vazquez, G. H., & Zarate, C. A. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.09.071 · Cited by 408
Cohen, S. P., Bhatia, A., Buvanendran, A., Schwenk, E. S., Wasan, A. D., Hurley, R. W., Viscusi, E. R., Narouze, S., Davis, F. N., Ritchie, E. C., et al. (2018) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000808 · Cited by 350
“5 mg/kg over 40 minutes was more effective than very low dosages, although the small numbers of patients involved and significant heterogeneity in study design limited the conclusions.(220,221) However, a recent consensus statement on ketamine use for depression found that alternative lower dosage schemes could be app…”
Ketamine and rapid antidepressant action: New treatments and novel synaptic signaling mechanisms
Krystal, J. H., Kavalali, E. T., & Monteggia, L. M. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01629-w · Cited by 262
“Three randomized placebo-controlled studies in treatment-resistant depression and PTSD [35, 47 – 49] suggest that lowering the dose by approximately half or more ( ≤ 0.2 mg/kg) is associated with loss of antidepressant ef fi cacy, while doubling the ketamine dose (1.0 mg/kg) increases the intensity…”
BackgroundInfluentialIntravenous arketamine for treatment-resistant depression: open-label pilot study
Leal, G. C., Bandeira, I. D., Correia-Melo, F. S., Telles, M., Mello, R. P., Vieira, F., Lima, C. S., Jesus-Nunes, A. P., Guerreiro-Costa, L. N. F., Marback, R. F., et al. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-020-01110-5 · Cited by 257
Self-citationYang, C., Ren, Q., Qu, Y., Zhang, J.-C., Ma, M., Dong, C., & Hashimoto, K. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.05.016 · Cited by 250
Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development
Schenberg, E. E. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00733 · Cited by 240
Ketamine and depression: a narrative review
Corriger, A., & Pickering, G. (2019) · Drug Design, Development and Therapy · doi:10.2147/dddt.s221437 · Cited by 211
Su, T.-P., Chen, M.-H., Li, C.-T., Lin, W.-C., Hong, C.-J., Gueorguieva, R., Tu, P.-C., Bai, Y.-M., Cheng, C.-M., & Krystal, J. H. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.94 · Cited by 209
“The dose-related efficacy of ketamine in the current study is consistent with an earlier meta-analysis that suggested that, across studies, higher subanesthetic ketamine doses were more effective (Xu et al, 2016).”
Witt, K., Potts, J., Hubers, A., Grunebaum, M. F., Murrough, J. W., Loo, C., Cipriani, A., & Hawton, K. (2020) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419883341 · Cited by 202
“These effects were apparent up to 72 hours post-infusion, in line with some previous work (Wilkinson et al., 2018; Xu et al., 2016), although considerable heterogeneity was associated with the estimates.”
BackgroundResultSelf-citationCorreia-Melo, F. S., Leal, G. C., Vieira, F., Jesus-Nunes, A. P., Mello, R. P., Magnavita, G., Caliman-Fontes, A. T., Echegaray, M. V. F., Bandeira, I. D., Silva, S. S., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.11.086 · Cited by 193
Self-citationPham, T. H., & Gardier, A. M. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.017 · Cited by 186
Chang, L., Zhang, K., Pu, Y., Qu, Y., Wang, S.-M., Xiong, Z., Ren, Q., Dong, C., Fujita, Y., & Hashimoto, K. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.04.008 · Cited by 176
Ketamine for the treatment of major depression: a systematic review and meta-analysis
Nikolin, S., Rodgers, A., Schwaab, A., Bahji, A., Zarate, C., Vazquez, G., & Loo, C. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.102127 · Cited by 172
Self-citationKryst, J., Kawalec, P., Mitoraj, A. M., Pilc, A., Lasoń, W., & Brzostek, T. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00097-z · Cited by 159
George, D., Gálvez, V., Martin, D., Kumar, D., Leyden, J., Hadzi-Pavlovic, D., Harper, S., Brodaty, H., Glue, P., Taylor, R., et al. (2017) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2017.06.007 · Cited by 149
Self-citationGlue, P., Medlicott, N. J., Harland, S., Neehoff, S., Anderson-Fahey, B., Le Nedelec, M., Gray, A., & McNaughton, N. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117705089 · Cited by 144
“, 2000) has now been replicated in numerous randomized controlled trials (RCTs) and case series (Xu et al., 2016).”
BackgroundSelf-citationKohtala, S. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00232-4 · Cited by 142
“The dose dependency of ketamine’s antidepressant effects has been further addressed in a systematic review and meta-analysis of nine ketamine trials for the treatment of depression [103].”
BackgroundKetamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression
Lener, M. S., Kadriu, B., & Zarate, C. A. (2017) · Drugs · doi:10.1007/s40265-017-0702-8 · Cited by 131
“A meta-analysis of seven clinical trials providing unpublished data on the suicide item component of either the HAM-D or the MADRS noted a significant reduction in suicidality severity score for the ketamine group at days 1 and 3 [59].”
Bobo, W. V., Vande Voort, J. L., Croarkin, P. E., Leung, J. G., Tye, S. J., & Frye, M. A. (2016) · Depression and Anxiety · doi:10.1002/da.22505 · Cited by 123
“A separate meta-analysis by Xu et al.[41] also reported large effects favoring ketamine for short-term positive response (pooled response rate 50 vs.”
BackgroundMethodInfluentialCognition in the Chronic Pain Experience: Preclinical Insights
Phelps, C. E., Navratilova, E., & Porreca, F. (2021) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2021.01.001 · Cited by 137
Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study
Cullen, K. R., Amatya, P., Roback, M. G., Albott, C. S., Westlund Schreiner, M., Ren, Y., Eberly, L. E., Carstedt, P., Samikoglu, A., Gunlicks-Stoessel, M., et al. (2018) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2018.0030 · Cited by 117
“4 mg/kg) (Xu et al. 2016) and that dose escalation from 0.”
Swainson, J., McGirr, A., Blier, P., Brietzke, E., Richard-Devantoy, S., Ravindran, N., Blier, J., Beaulieu, S., Frey, B. N., Kennedy, S. H., et al. (2021) · The Canadian Journal of Psychiatry · doi:10.1177/0706743720970860 · Cited by 110
Self-citationPerbet, S., Verdonk, F., Godet, T., Jabaudon, M., Chartier, C., Cayot, S., Guérin, R., Morand, D., Bazin, J.-É., Futier, E., et al. (2018) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2018.09.006 · Cited by 127
Glue, P., Neehoff, S. M., Medlicott, N. J., Gray, A., Kibby, G., & McNaughton, N. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118762073 · Cited by 100
“, 2000) has now been replicated in numerous randomised clinical trials and case series (Katalinic et al., 2013; Xu et al., 2016).”
BackgroundSelf-citationHuang, N., Hua, D., Zhan, G., Li, S., Zhu, B., Jiang, R., Yang, L., Bi, J., Xu, H., Hashimoto, K., et al. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2018.12.001 · Cited by 103
Glue, P., Neehoff, S., Sabadel, A., Broughton, L., Le Nedelec, M., Shadli, S., McNaughton, N., & Medlicott, N. J. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119874457 · Cited by 98
“The N-methyl-D-aspartate (NMDA) antagonist ketamine has broad rapid-onset activity across a range of treatment-resistant internalizing disorders: major depressive disorder (MDD) (Berman et al., 2000; Xu et al., 2016; Zarate et al., 2006), obsessive compulsive disorder (Feder et al.”
BackgroundInfluentialSelf-citationWilkinson, S. T., Holtzheimer, P. E., Gao, S., Kirwin, D. S., & Price, R. B. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.09.004 · Cited by 95
“4) (36), even in treatment-resistant depression (37) and bipolar depression (38).”
Glutamatergic Modulators in Depression
Henter, I. D., de Sousa, R. T., & Zarate, C. A. (2018) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000183 · Cited by 92
Identifying Ketamine Responses in Treatment-Resistant Depression Using a Wearable Forehead EEG
Cao, Z., Lin, C.-T., Ding, W., Chen, M.-H., Li, C.-T., & Su, T.-P. (2019) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2018.2877651 · Cited by 89
Price, R. B., Spotts, C., Panny, B., Griffo, A., Degutis, M., Cruz, N., Bell, E., Do-Nguyen, K., Wallace, M. L., Mathew, S. J., et al. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20220216 · Cited by 85
Brain Changes Associated With Long-Term Ketamine Abuse, A Systematic Review
Strous, J. F. M., Weeland, C. J., van der Draai, F. A., Daams, J. G., Denys, D. A. J. P., Lok, A., Schoevers, R. A., & Figee, M. (2022) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2022.795231 · Cited by 103
Gálvez, V., Li, A., Huggins, C., Glue, P., Martin, D., Somogyi, A. A., Alonzo, A., Rodgers, A., Mitchell, P. B., & Loo, C. K. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118760660 · Cited by 85
Self-citationRéus, G. Z., Manosso, L. M., Quevedo, J., & Carvalho, A. F. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105425 · Cited by 103
Dold, M., Bartova, L., Fugger, G., Kautzky, A., Souery, D., Mendlewicz, J., Papadimitriou, G. N., Dikeos, D., Ferentinos, P., Porcelli, S., et al. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy009 · Cited by 82
Price, R. B., Kissel, N., Baumeister, A., Rohac, R., Woody, M. L., Ballard, E. D., Zarate, C. A., Deakin, W., Abdallah, C. G., Feder, A., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01757-7 · Cited by 82
Loo, C. K. A., Glozier, N., Barton, D., Baune, B. T., Mills, N. T., Fitzgerald, P. B., Glue, P., Sarma, S., Gálvez, V., Hadži-Pavlović, D., et al. (2023) · The British Journal of Psychiatry · doi:10.1192/bjp.2023.79 · Cited by 102
Self-citationThe Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Zaretsky, T. G., Jagodnik, K. M., Barsic, R., Antonio, J. H., Bonanno, P. A., MacLeod, C., Pierce, C., Carney, H., Morrison, M. T., Saylor, C. F., et al. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666231027111147 · Cited by 104
Fountoulakis, K. N., Yatham, L. N., Grunze, H., Vieta, E., Young, A. H., Blier, P., Tohen, M., Kasper, S., & Moeller, H. J. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz064 · Cited by 77
Mashour, G. A., Abdallah, A. B., Pryor, K. O., El-Gabalawy, R. M., Vlisides, P. E., Jacobsohn, E., Lenze, E. J., Maybrier, H. R., Veselis, R. A., & Avidan, M. S. (2018) · British Journal of Anaesthesia · doi:10.1016/j.bja.2018.03.030 · Cited by 80
Bahji, A., Zarate, C. A., & Vazquez, G. H. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2047928 · Cited by 73
“and esketamine are both evidence-based treatments for depression [8,11,13,15,36,51,52,64,65,74], only esketamine has”
Higgins, G. A., Carroll, N. K., Brown, M., MacMillan, C., Silenieks, L. B., Thevarkunnel, S., Izhakova, J., Magomedova, L., DeLannoy, I., & Sellers, E. M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.640241 · Cited by 69
Novel rapid-acting glutamatergic modulators: Targeting the synaptic plasticity in depression
Wang, Y., Wang, X., Feng, S., Chen, N., Wang, Z., & Zhang, Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105761 · Cited by 69
Ketamine and Magnesium for Refractory Neuropathic Pain: A Randomized, Double-blind, Crossover Trial
Pickering, G., Pereira, B., Morel, V., Corriger, A., Giron, F., Marcaillou, F., Bidar-Beauvallot, A., Chandeze, E., Lambert, C., Bernard, L., et al. (2020) · Anesthesiology · doi:10.1097/aln.0000000000003345 · Cited by 69
Adjunctive ketamine in electroconvulsive therapy: Updated systematic review and meta-analysis
McGirr, A., Berlim, M. T., Bond, D. J., Chan, P. Y., Yatham, L. N., & Lam, R. W. (2017) · British Journal of Psychiatry · doi:10.1192/bjp.bp.116.195826 · Cited by 68
Self-citationA Review of Nonanesthetic Uses of Ketamine
Pribish, A., Wood, N., & Kalava, A. (2020) · Anesthesiology Research and Practice · doi:10.1155/2020/5798285 · Cited by 67
“*is effect has been noted in both unipolar and bipolar depression [26], although effect duration may be shorter in patients with bipolar disorder [27].”
BackgroundKetamine as a therapeutic agent for depression and pain: mechanisms and evidence
Subramanian, S., Haroutounian, S., Palanca, B. J. A., & Lenze, E. J. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120152 · Cited by 76
Milak, M. S., Rashid, R., Dong, Z., Kegeles, L. S., Grunebaum, M. F., Ogden, R. T., Lin, X., Mulhern, S. T., Suckow, R. F., Cooper, T. B., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.13211 · Cited by 63
Papp, M., Gruca, P., Lason-Tyburkiewicz, M., & Willner, P. (2017) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000259 · Cited by 63
“…lists 15 open and 10 controlled clinical trials (Abdallah et al., 2015), and a meta-analysis of the controlled studies confirmed significantly higher rates of response and remission, relative to placebo, 1 and 3 days after a single ketamine infusion, but a lesser effect at 7 days (Xu et al., 2016).”
BackgroundResultTian, Z., Dong, C., Fujita, A., Fujita, Y., & Hashimoto, K. (2018) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2018.07.003 · Cited by 62
Kopelman, J., Keller, T. A., Panny, B., Griffo, A., Degutis, M., Spotts, C., Cruz, N., Bell, E., Do-Nguyen, K., Wallace, M. L., et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02451-0 · Cited by 60
McGirr, A., LeDue, J., Chan, A. W., Xie, Y., & Murphy, T. H. (2017) · Brain · doi:10.1093/brain/awx142 · Cited by 59
“, 2016) results in robust antidepressant effects within minutes to hours in humans (McGirr et al., 2015; Xu et al., 2016), providing a unique window for capturing functional network changes and improving mechanistic understanding.”
BackgroundSelf-citationWhittaker, E., Dadabayev, A. R., Joshi, S. A., & Glue, P. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211056743 · Cited by 56
Self-citationNovel treatment options in depression and psychosis
Ceskova, E., & Silhan, P. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s157475 · Cited by 56
“However, there is substantial heterogeneity in clinical response, and ketamine’s underlying mechanisms of action are not entirely understood.(14,15) The observation that a single intravenous dose of glutamatergic modulator ketamine produces a robust and rapid AD effect was a turning point that opened the way for other…”
BackgroundZheng, W., Li, X.-H., Zhu, X.-M., Cai, D.-B., Yang, X.-H., Ungvari, G. S., Ng, C. H., Ning, Y.-P., Hu, Y.-D., He, S.-H., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.02.044 · Cited by 55
Kim, J.-W., & Monteggia, L. M. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112378 · Cited by 53
Feeney, A., & Papakostas, G. I. (2023) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2023.02.003 · Cited by 64
Vidal, S., Gex-Fabry, M., Bancila, V., Michalopoulos, G., Warrot, D., Jermann, F., Dayer, A., Sterpenich, V., Schwartz, S., Vutskits, L., et al. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000960 · Cited by 52
Siegel, J. S., Palanca, B. J. A., Ances, B. M., Kharasch, E. D., Schweiger, J. A., Yingling, M. D., Snyder, A. Z., Nicol, G. E., Lenze, E. J., & Farber, N. B. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05762-6 · Cited by 50
Lack of metabolism in (R)-ketamine’s antidepressant actions in a chronic social defeat stress model
Zhang, K., Fujita, Y., & Hashimoto, K. (2018) · Scientific Reports · doi:10.1038/s41598-018-22449-9 · Cited by 49
Xiong, Z., Fujita, Y., Zhang, K., Pu, Y., Chang, L., Ma, M., Chen, J., & Hashimoto, K. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.111904 · Cited by 49
The Antidepressant Effect of Ketamine Is Dampened by Concomitant Benzodiazepine Medication
Andrashko, V., Novak, T., Brunovsky, M., Klirova, M., Sos, P., & Horacek, J. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00844 · Cited by 48
Glue, P., Medlicott, N. J., Neehoff, S., Surman, P., Lam, F., Hung, N., & Hung, C.-T. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320922474 · Cited by 42
Self-citationStudies with psychedelic drugs in human volunteers
Sellers, E. M., Romach, M. K., & Leiderman, D. B. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.029 · Cited by 42
“Replicated studies include lowdose ketamine in treatment resistant depression (Berman et al., 2000; Xu et al., 2016).”
Glue, P., Medlicott, N. J., Surman, P., Lam, F., Hung, N. A., & Hung, C. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1573 · Cited by 42
Self-citationKetamine for Treatment of Mood Disorders and Suicidality: A Narrative Review of Recent Progress
Kritzer, M. D., Mischel, N., Young, J. R., Lai, C. S., Masand, P. S., Szabo, S. T., & Mathew, S. J. (2021) · Annals of Clinical Psychiatry · doi:10.12788/acp.0048 · Cited by 45
Suicide Has Many Faces, So Does Ketamine: a Narrative Review on Ketamine’s Antisuicidal Actions
Lengvenytė, A., Olié, É., & Courtet, P. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-1108-y · Cited by 45
Smith-Apeldoorn, S. Y., Veraart, J. K. E., Kamphuis, J., van Asselt, A. D. I., Touw, D. J., aan het Rot, M., & Schoevers, R. A. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2359-1 · Cited by 39
Radford, K. D., Park, T. Y., Lee, B. H., Moran, S., Osborne, L. A., & Choi, K. H. (2016) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2016.12.014 · Cited by 44
“For example, clinicians administer low-dose IV ketamine infusions to treat chronic pain (Prommer, 2012), depression (Xu et al., 2016), and PTSD (Feder et al.”
Conley, A. A., Norwood, A. E. Q., Hatvany, T. C., Griffith, J. D., & Barber, K. E. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05825-8 · Cited by 39
Use of ketamine and esketamine for depression: an overview of systematic reviews with meta-analyses
Lima, T. D. M., Visacri, M. B., & Aguiar, P. M. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03216-8 · Cited by 50
Herzog, D. P., Wegener, G., Lieb, K., Müller, M. B., & Treccani, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040949 · Cited by 39
“Among those, ketamine, a non-competitive NMDA receptor antagonist, originally introduced as a dissociative anaesthetic, revealed to induce a rapid (within hours) and sustained (up to 1 week) antidepressant effect in treatment-resistant [58,59].”
BackgroundGarel, N., Drury, J., Lévesque, J. T., Goyette, N., Lehmann, A., Looper, K. J., Erritzøe, D., Dames, S., Turecki, G., Rej, S., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1268832 · Cited by 40
“On meta-analysis, approximately half of TRD patients will respond (>50% improvement in symptoms of depressions) within hours or days of a single 40-min IV ketamine infusion (23, 24).”
BackgroundEfficacy of Esketamine in the Treatment of Depression With Psychotic Features: A Case Series
Ajub, E., & Lacerda, A. L. T. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.06.011 · Cited by 35
Rodolico, A., Cutrufelli, P., Francesco, A. D., Aguglia, A., Catania, G., Concerto, C., Cuomo, A., Fagiolini, A. M., Lanza, G., Mineo, L., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1325399 · Cited by 45
Maintenance Ketamine Therapy for Treatment-Resistant Depression
Archer, S., Chrenek, C., & Swainson, J. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000894 · Cited by 34
Zhang, K., Toki, H., Fujita, Y., Ma, M., Chang, L., Qu, Y., Harada, S., Nemoto, T., Mizuno‐Yasuhira, A., Yamaguchi, J., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5017-2 · Cited by 33
Low-dose ketamine for treatment resistant depression in an academic clinical practice setting
Feifel, D., Malcolm, B., Boggie, D., & Lee, K. C. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.06.043 · Cited by 34
“…increase hemodynamic parameters, and about 50% of our sample population experienced a transient increase in blood pressure and/or heart rate, but none of them required medication treatment or infusion interruption for these changes (Iadarola et al., 2015; Romeo et al., 2015; Xu et al., 2015b).”
BackgroundMethodInfluentialIshiwata, S., Hattori, K., Sasayama, D., Teraishi, T., Miyakawa, T., Yokota, Y., Matsumura, R., Nishikawa, T., & Kunugi, H. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.09.035 · Cited by 31
Lascelles, K. M., Marzano, L., Brand, F., Trueman, H., McShane, R. H., & Hawton, K. E. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-029108 · Cited by 36
Gálvez, V., McGuirk, L., & Loo, C. K. A. (2016) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2016.1252464 · Cited by 33
“There is literature suggesting that antidepressant response with ketamine is dose-dependent (Loo et al. 2016) and that low doses of ketamine (0.5mg/kg) are more effective than very low doses (<0.5mg/kg) (Xu et al. 2016).”
BackgroundSelf-citationUrothelial toxicity of esketamine in the treatment of depression
Findeis, H., Sauer, C., Cleare, A. J., Bauer, M., & Ritter, P. S. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05611-y · Cited by 29
Glue, P., Russell, B., & Medlicott, N. J. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-03047-z · Cited by 33
Self-citationKeeler, J. L., Treasure, J. L., Himmerich, H., Brendle, M., Moore, C., & Robison, R. J. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1181447 · Cited by 30
Pham, T. H., Defaix, C., Nguyen, T. M. L., Mendez‐David, I., Tritschler, L., David, D. J. P., & Gardier, A. M. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172913 · Cited by 30
Le, T. T., Vincenzo, J. D. D., Teopiz, K. M., Lee, Y. L., Cha, D. S., Lui, L. M. W., Rodrigues, N. B., Ho, R., Cao, B., Lin, K., et al. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114231 · Cited by 28
López-Díaz, Á., Fernández-González, J. L., Luján-Jiménez, J. E., Galiano-Rus, S., & Gutiérrez-Rojas, L. (2017) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316675578 · Cited by 27
Xu, J. J., Herndon, C. M., Anderson, S., Getson, P., Foorsov, V., Harbut, R. E., Moskovitz, P. A., & Harden, R. N. (2018) · Pain Medicine · doi:10.1093/pm/pny024 · Cited by 27
Kohtala, S., Theilmann, W., Rosenholm, M., Müller, H. K., Kiuru, P. S., Wegener, G., Yli‐Kauhaluoma, J. T., & Rantamäki, T. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107684 · Cited by 29
Kučerová, J., Babinská, Z., Štark, T., & Micale, V. (2017) · Neurotoxicity Research · doi:10.1007/s12640-017-9718-9 · Cited by 28
Larrea, A., Sánchez-Sánchez, L., Díez-Martín, E., Elexpe, A., Torrecilla, M., Astigarraga, E., & Barreda‐Gómez, G. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061727 · Cited by 34
Tarrés-Gatius, M., Miquel-Rio, L., Campa, L., Artigas, F., & Castañé, A. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-01110-y · Cited by 29
Kingir, E., Sevinc, C., & Ünal, G. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109468 · Cited by 30
Intravenous infusion of xenon-containing liposomes generates rapid antidepressant-like effects
Dandekar, M. P., Peng, T., McPherson, D. D., Quevedo, J., Soares, J. C., & Huang, S. L. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.03.011 · Cited by 25
Can we confidently use ketamine as a clinical treatment for depression?
Loo, C. K. A. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30480-7 · Cited by 24
Self-citationDerntl, B., Hornung, J., Şen, Z. D., Čolić, L., Li, M., & Walter, M. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00616 · Cited by 23
“, 2013), even for low doses (Xu et al., 2016), leading to rapid acting and long lasting effects.”
Background
Metadata
- Authors
- Xu, Y., Hackett, M., Carter, G., Loo, C., Gálvez, V., Glozier, N., Glue, P., Lapidus, K., McGirr, A., Somogyi, A. A., Mitchell, P. B., & Rodgers, A.
- Affiliations
- The University of Sydney (AU)
- Corresponding author
- Loo, Colleen
- ORCID
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-11-17
- Volume
- 19
- Issue
- 4
- Pages
- pyv124
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC4851268
- OpenAlex
- W2197394318
- Cited by
- 226
- References
- 44
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 22 · 2023: 22 · 2022: 22 · 2021: 20 · 2020: 29 · 2019: 26 · 2018: 28 · 2017: 24 · 2016: 13
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
- UNSWorks (UNSW Sydney) (submittedVersion, cc-by-nc-nd)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by)
- Figshare (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Spiral (Imperial College London) (submittedVersion, other-oa)
- NOVA (University of Newcastle Australia) (submittedVersion)
- Funders
- National Institute of Mental Health (K23MH104465)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- ketamine, major depressive disorder, low-dose ketamine, rapid antidepressant effects, dose-response relationship, remission, response rate, suicidality, bipolar disorder, crossover trial, safety and tolerability
- MeSH terms
- Antidepressive Agents, Major Depressive Disorder, Humans, Ketamine, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.